Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone capsule in advanced solid tumors
NCT06730581Phase 2Not yet recruiting
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Allosteric Modulators
01
Overview
A Phase 2 trial of utidelone in gastric cancer (GC), ovarian cancer, cholangiocarcinoma (CCA), esophageal cancer, hepatocellular carcinoma (HCC), sponsored by Beijing Biostar Pharmaceuticals Co., Ltd.. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
utidelone
03
Conditions
gastric cancer (GC)ovarian cancercholangiocarcinoma (CCA)esophageal cancerhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06730581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06730581.